SNDX

Syndax Pharmaceuticals, Inc. (SNDX) | Rumor.io

Syndax Pharmaceuticals

SNDX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,541

Bullish sentiment (50-day avg)95%

Price to earnings ratio-5.43

Market capitalization1.6B

Earnings per share-2.51

Dividend yield (TTM)—

Revenue (annual)172.4M

Net income (annual)-285.4M

Social

What share of all stock conversation is about SNDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Aug 5

Syndax Pharmaceuticals, Inc. (SNDX) reported a 92% jump in revenue YoY, but missed earnings expectations, with the market reacting negatively to the Q2 FY2026 results.
The company's Revufenib product is expected to continue gaining traction, with post-transplant use increasing and revenues stacking nicely going forward.
Syndax's Q4 readouts are expected to be a key catalyst for the stock, with a potential $2B+ peak sales in the US for Revufenib and the inclusion of NUP98r in NCCN guidelines adding another 1,000 to 2,000 patients.

Generated by AI

Sentiment

Of the messages about SNDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +90	35% -56.64	86.62% -2.12
Bearish	0%	0% -90	65% +56.64	13.38% +2.12

Bullish· Jul 14

Syndax Pharmaceuticals' ($SNDX) R&D event unveiled two new assets addressing areas of high unmet need, with phase 1 trials set to start in Q4 and POC data expected next year.
The company's novel menin for myelofibrosis capitalizes on a recent publication, with phase 1 trials expected to drive continued growth and revenue increases, including $200M annualized revenue.
With 3 FDA approvals and 8+ ongoing clinical trials, $SNDX is poised for long-term growth, making it a strong portfolio anchor stock with a bright and foundationalized future.

Bearish· Nov 3

* The analyst's prediction for SNDX is lower than most targets, suggesting a potential decrease in value.
* The stock has experienced significant price drops due to large trades, including a 2-dollar drop with 17k shares traded and a price drop from $13.75 to $10.9.
* SNDX's revenue fell short of expectations by approximately $1.5 million, leading to a panic stop-loss in low volume.

Generated by AI

Topics

Of the messages about SNDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	88.89%	95.65%	66.22%	32.53%
Technical Analysis	0%	0%	32.43%	5.9%
Analysts	11.11%	4.35%	1.35%	32.42%
Earnings	0%	0%	0%	4.75%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	24.4%

Earnings· Aug 7

Syndax Pharmaceuticals reported earnings that beat expectations by $0.13.
The company also beat revenue expectations.
Syndax Pharmaceuticals reported a loss of $0.74 per share, better than the consensus estimate of a loss of $0.91.

Analysts· May 26

Syndax Pharmaceuticals ($SNDX) has been given a "Buy" rating by Nomura, Zacks Investment Research, and Citigroup.
The price target for $SNDX has been lowered to $23.00 at Barclays, and the company has been downgraded to "Neutral" at HC Wainwright.
Analysts have a 87% consensus to buy $SNDX, with a consensus target price of $20.33.

Announcements· Oct 24

The FDA has approved Revumenib (Revuforj) for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation in adult and pediatric patients.
This is the second indication for Revumenib, which has been approved in less than one year, further solidifying Syndax's leadership in menin inhibition.
The approval has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for relapsed or refractory NPM1 mutated AML.

Technical Analysis· Apr 28

$SNDX is in a bear flag, which may indicate a downward trend.
The stock has a cup and handle formation, which could be a bullish sign and indicate a potential move to the $20 area.
There is support at the $18.7 area, which could be a key level for the stock's price movement.

Generated by AI

Community

Of the messages about SNDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	90.91%	89.09%	60.68%	49.48%
Newcomers	9.09%	10.91%	39.32%	50.52%

Regulars· Aug 5

The company's Q2 results were mixed, with a net loss down 44% and revenue missing expectations, but post-transplant use of Revuforj is increasing, and the market expects a larger patient base to contribute to future revenue.
The Q4 readouts for Revumenib are expected to be key, and the company's market capitalization of $1.5B and the $2B TAM for menin inhibitors suggest space for both players, including Kura.
The recent fund-raising round attracted new investors, but the company's recent Q2 results may have been a disappointment to them, with a net loss and missed revenue expectations.

Newcomers· Jul 17

Newcomers are excited about the potential of Syndax Pharmaceuticals' SqueezeFinder technology, with one user mentioning its latest data.
Investors are looking for more information about the company's pipeline and how SqueezeFinder fits into its overall strategy.
Some users are speculating about the potential for Syndax Pharmaceuticals to partner with other companies to further develop its technology.

Generated by AI

News

Jefferies reiterates Buy on Syndax stock ahead of IPF data

1d agoInvesting.com

Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases (SNDX)

Syndax achieved FDA approval for Revuforj in r/r mNPM1 AML and is pursuing pivotal studies to expand into 1st-line AML populations. Read why SNDX is a Strong Buy.

2d agoSeeking Alpha

Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts (NASDAQ:SNDX)

Syndax Pharmaceuticals, Inc. has an attractive valuation, key readouts in Q4, and an expanding pipeline. Read more on SNDX stock here.

4d agoSeeking Alpha

Syndax at H.C. Wainwright conference: recurring revenue takes center stage

14d agoInvesting.com

Syndax Pharmaceuticals at Citigroup’s Biopharma Back to School Summit 2026: revuforj gains

19d agoInvesting.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting comm

26d agoYahoo Finance

Also Discussed

Investors talking about SNDX also mention

#	Name	Attention
1	Kura Oncology, Inc.KURA	0%+0
2	IDEAYA Biosciences Inc.IDYA	0%0
3	SWTX - SpringWorks Therapeutics, Inc.	——
4	DAWN - Day One Biopharmaceuticals, Inc.	——
5	Incyte Corp.INCY	0%new
6	Nuvation Bio Inc.NUVB	0%0
7	Arcus Biosciences, Inc.RCUS	0%new
8	Mineralys Therapeutics, Inc.MLYS	0%+0
9	MacroGenics Inc.MGNX	0%0
10	Replimune Group, Inc.REPL	0%0

Syndax Pharmaceuticals, Inc.

Healthcare
Biotechnology

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. Its current portfolio centers on treatments for hematologic malignancies and serious immune-related conditions, with products that address acute leukemias and chronic graft-versus-host disease. The company’s work spans research, regulatory advancement, and commercial execution, combining clinical development with product launch and market support. Syndax Pharmaceuticals also collaborates with partners to broaden access to its therapies and strengthen its presence in oncology and related specialty care markets. Headquartered in New York, New York, Syndax Pharmaceuticals, Inc. plays a role in advancing targeted treatment options for patients with high unmet medical needs.

Website

Location

730 Third Avenue

New York, NY, 10017

United States

Social

What share of all stock conversation is about SNDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Aug 5

Syndax Pharmaceuticals, Inc. (SNDX) reported a 92% jump in revenue YoY, but missed earnings expectations, with the market reacting negatively to the Q2 FY2026 results.
The company's Revufenib product is expected to continue gaining traction, with post-transplant use increasing and revenues stacking nicely going forward.
Syndax's Q4 readouts are expected to be a key catalyst for the stock, with a potential $2B+ peak sales in the US for Revufenib and the inclusion of NUP98r in NCCN guidelines adding another 1,000 to 2,000 patients.

Generated by AI

Sentiment

Of the messages about SNDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +90	35% -56.64	86.62% -2.12
Bearish	0%	0% -90	65% +56.64	13.38% +2.12

Bullish· Jul 14

Syndax Pharmaceuticals' ($SNDX) R&D event unveiled two new assets addressing areas of high unmet need, with phase 1 trials set to start in Q4 and POC data expected next year.
The company's novel menin for myelofibrosis capitalizes on a recent publication, with phase 1 trials expected to drive continued growth and revenue increases, including $200M annualized revenue.
With 3 FDA approvals and 8+ ongoing clinical trials, $SNDX is poised for long-term growth, making it a strong portfolio anchor stock with a bright and foundationalized future.

Bearish· Nov 3

* The analyst's prediction for SNDX is lower than most targets, suggesting a potential decrease in value.
* The stock has experienced significant price drops due to large trades, including a 2-dollar drop with 17k shares traded and a price drop from $13.75 to $10.9.
* SNDX's revenue fell short of expectations by approximately $1.5 million, leading to a panic stop-loss in low volume.

Generated by AI

Topics

Of the messages about SNDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	88.89%	95.65%	66.22%	32.53%
Technical Analysis	0%	0%	32.43%	5.9%
Analysts	11.11%	4.35%	1.35%	32.42%
Earnings	0%	0%	0%	4.75%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	24.4%

Earnings· Aug 7

Syndax Pharmaceuticals reported earnings that beat expectations by $0.13.
The company also beat revenue expectations.
Syndax Pharmaceuticals reported a loss of $0.74 per share, better than the consensus estimate of a loss of $0.91.

Analysts· May 26

Syndax Pharmaceuticals ($SNDX) has been given a "Buy" rating by Nomura, Zacks Investment Research, and Citigroup.
The price target for $SNDX has been lowered to $23.00 at Barclays, and the company has been downgraded to "Neutral" at HC Wainwright.
Analysts have a 87% consensus to buy $SNDX, with a consensus target price of $20.33.

Announcements· Oct 24

The FDA has approved Revumenib (Revuforj) for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation in adult and pediatric patients.
This is the second indication for Revumenib, which has been approved in less than one year, further solidifying Syndax's leadership in menin inhibition.
The approval has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for relapsed or refractory NPM1 mutated AML.

Technical Analysis· Apr 28

$SNDX is in a bear flag, which may indicate a downward trend.
The stock has a cup and handle formation, which could be a bullish sign and indicate a potential move to the $20 area.
There is support at the $18.7 area, which could be a key level for the stock's price movement.

Generated by AI

Community

Of the messages about SNDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	90.91%	89.09%	60.68%	49.48%
Newcomers	9.09%	10.91%	39.32%	50.52%

Regulars· Aug 5

The company's Q2 results were mixed, with a net loss down 44% and revenue missing expectations, but post-transplant use of Revuforj is increasing, and the market expects a larger patient base to contribute to future revenue.
The Q4 readouts for Revumenib are expected to be key, and the company's market capitalization of $1.5B and the $2B TAM for menin inhibitors suggest space for both players, including Kura.
The recent fund-raising round attracted new investors, but the company's recent Q2 results may have been a disappointment to them, with a net loss and missed revenue expectations.

Newcomers· Jul 17

Newcomers are excited about the potential of Syndax Pharmaceuticals' SqueezeFinder technology, with one user mentioning its latest data.
Investors are looking for more information about the company's pipeline and how SqueezeFinder fits into its overall strategy.
Some users are speculating about the potential for Syndax Pharmaceuticals to partner with other companies to further develop its technology.

Generated by AI

Syndax Pharmaceuticals

Social

Aug 5

Bullish· Jul 14

Bearish· Nov 3

Earnings· Aug 7

Analysts· May 26

Announcements· Oct 24

Technical Analysis· Apr 28

Regulars· Aug 5

Newcomers· Jul 17

Jefferies reiterates Buy on Syndax stock ahead of IPF data

Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases (SNDX)

Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts (NASDAQ:SNDX)

Syndax at H.C. Wainwright conference: recurring revenue takes center stage

Syndax Pharmaceuticals at Citigroup’s Biopharma Back to School Summit 2026: revuforj gains

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Also Discussed

Syndax Pharmaceuticals, Inc.

Company Information

Location

Jefferies reiterates Buy on Syndax stock ahead of IPF data

Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases (SNDX)

Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts (NASDAQ:SNDX)

Syndax at H.C. Wainwright conference: recurring revenue takes center stage

Syndax Pharmaceuticals at Citigroup’s Biopharma Back to School Summit 2026: revuforj gains

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Also Discussed

Social

Aug 5

Bullish· Jul 14

Bearish· Nov 3

Earnings· Aug 7

Analysts· May 26

Announcements· Oct 24

Technical Analysis· Apr 28

Regulars· Aug 5

Newcomers· Jul 17